scholarly journals High-Dose Versus Low-Dose Systemic Steroids in the Treatment of Acute Exacerbations of Chronic Obstructive Pulmonary Disease: Systematic Review

2016 ◽  
Vol 3 (2) ◽  
pp. 580-588
Author(s):  
Diego Bonilla Arcos ◽  
Jerry A. Krishnan ◽  
R. William Vandivier ◽  
Jonathan E. Sevransky ◽  
William Checkley ◽  
...  
Keyword(s):  
Systematic Review ◽  
Chronic Obstructive Pulmonary Disease ◽  
Pulmonary Disease ◽  
Low Dose ◽  
Chronic Obstructive ◽  
High Dose ◽  
Obstructive Pulmonary Disease ◽  
Systemic Steroids ◽  
Acute Exacerbations

Optimal glucocorticoid dose and the effects on mortality, length of stay, and readmission rates in patients diagnosed with acute exacerbation of chronic obstructive pulmonary disease (AECOPD)

2019 ◽  
Vol 67 (8) ◽  
pp. 1161-1164
Author(s):  
Asim Kichloo ◽  
Michael Aljadah ◽  
Navya Vipparla ◽  
Farah Wani
Keyword(s):  
Chronic Obstructive Pulmonary Disease ◽  
Pulmonary Disease ◽  
Acute Exacerbation ◽  
Low Dose ◽  
Future Research ◽  
Chronic Obstructive ◽  
High Dose ◽  
Readmission Rates ◽  
Glucocorticoid Treatment ◽  
Obstructive Pulmonary Disease

The burden of acute exacerbation of chronic obstructive pulmonary disease (AECOPD) is staggering on a national and global level. Yet, surprisingly, there is a profound lack of treatment standardization with glucocorticoids in the treatment of AECOPD. In this review, we bring attention to specific literature that use a cut-off of 60 mg prednisone equivalent per day when distinguishing between high-dose and low-dose glucocorticoid treatment. We hope this review encourages future research to begin incrementally lowering the cut-off dose of 60 mg to discover if mortality, length of hospital stays, and readmission rates change between high-dose and low-dose glucocorticoid treatment. The final hope would be to establish an optimal glucocorticoid dose to treat AECOPD and eliminate treatment ambiguity.

Sign in / Sign up

Export Citation Format

Share Document